Page last updated: 2024-09-03

imatinib mesylate and Sclerosis, Systemic

imatinib mesylate has been researched along with Sclerosis, Systemic in 53 studies

Research

Studies (53)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (32.08)	29.6817
2010's	32 (60.38)	24.3611
2020's	4 (7.55)	2.80

Authors

Authors	Studies
Breda, S; Cagnone, M; Calderan, L; Cavagna, L; Codullo, V; Colombo, M; Cova, E; Distler, JHW; Frangipane, V; Giustra, M; Malatesta, M; Meloni, F; Montecucco, C; Morosini, M; Pacini, C; Pandolfi, L; Prosperi, D; Recalde, H	1
Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A	1
Kim, KJ; Moon, SJ; Park, KS; Tagkopoulos, I	1
Ciaffi, J; Ciccia, F; Cipriani, P; Giacomelli, R; Liakouli, V; Meliconi, R; Ruscitti, P; Ursini, F	1
Butt, ZA; Howard, D; Ng, WL; Osman, K	1
Jimenez, SA; Wermuth, PJ	1
Abtin, F; Divekar, AA; Furst, DE; Kafaja, S; Khanna, D; Saggar, R; Singh, RR; Valera, I	1
Barz, V; Bertrand, J; Ciarimboli, G; Distler, J; Edemir, B; Harrach, S; Pap, T; Pavenstädt, H; Schlatter, E	1
Assassi, S; Chang, J; Charles, J; Feghali-Bostwick, C; Ferguson, EC; Furst, DE; Graham, TA; Khanna, D; Mayes, MD; Tan, FK; Wu, M	1
Abraham, D; Dees, C; Denton, CP; Distler, A; Distler, O; Gay, RE; Gay, S; Hw Distler, J; Khan, K; Maurer, B; Michel, BA	1
Fancher, KM; Green, MR; Newton, MD	1
Bombardieri, S; Bosello, S; Corvetta, A; Del Papa, N; Faggioli, P; Fraticelli, P; Gabrielli, A; Gabrielli, B; Gerli, R; Gerosa, M; Giacomelli, R; Lunardi, C; Malorni, W; Moroncini, G; Pomponio, G; Riboldi, P; Valentini, G	1
Hinchcliff, ME; Johnson, JA; Lomasney, J; Varga, J	1
Bibi, Y; Gottlieb, AB	1
Asano, Y; Blaszczyk, M; Jablonska, S; Nakerakanti, S; Pannu, J; Smith, E; ten Dijke, P; Trojanowska, M	1
Dik, WA; Hooijkaas, H; Thio, HB; van Daele, PL; van Hagen, PM; van Hal, PT; van Laar, JA	1
High, WA; Kay, J	1
Bruno, B; Catteau, B; Coiteux, V; Jouet, JP; Magro, L; Yakoub-Agha, I	1
Distler, JH; Distler, O	2
Arroyo, LH; Baran, DA; Rivera, V; Rosenstein, ED; Sabnani, I; Tsang, P; Zubair, M; Zucker, MJ	1
Akhmetshina, A; Busch, N; Dees, C; Distler, JH; Distler, O; Schett, G; Venalis, P; Zwerina, J	1
Bovenschulte, H; Dumitrescu, D; Erdmann, E; Rosenkranz, S; ten Freyhaus, H	1
Apostolidis, J; Baltadakis, I; Evangelou, K; Gorgoulis, VG; Harhalakis, N; Karakasis, D; Papadakis, V; Sfikakis, PP	1
Au, K; Clements, PJ; Furst, DE; Khanna, D; Tashkin, DP	1
Kameda, H	1
Asano, Y	1
Beyer, C; Distler, JH; Distler, O	1
Saito, K; Sawamukai, N; Shimajiri, S; Tanaka, Y; Yamaoka, K; Yukawa, S	1
Asano, Y; Bujor, AM; Trojanowska, M	1
Jamal, S; Johnson, SR; Phumethum, V	1
Distler, JH; Distler, O; Iwamoto, N	1
Gordon, J; Spiera, R	1
Boin, F; Manno, R	1
Asano, Y; Bujor, AM; Haines, P; Lafyatis, R; Trojanowska, M	1
Asano, Y; Hatano, M; Kawashima, T; Kinugawa, K; Nagai, R; Sato, S; Tamaki, Z; Tomita, M; Yao, A	1
Jiménez, SA; Mendoza, FA	1
Abtin, F; Assassi, S; Clements, PJ; Furst, DE; Khanna, D; Maranian, P; Mayes, MD; Saggar, R; Singh, RR	1
Sfikakis, PP	1
Abtin, F; Divekar, AA; Furst, DE; Khanna, D; Maranian, P; Saggar, R; Singh, RR	1
Mouthon, L	1
Bournia, VK; Evangelou, K; Sfikakis, PP	1
Chen, XX; Gu, YY; Guo, L; Ye, S; Zou, HJ	1
Dees, C; Del Galdo, F; Distler, A; Distler, JH; Distler, O; Egberts, F; Palumbo-Zerr, K; Schett, G; Spriewald, BM; Tinazzi, I; Tomcik, M; Vollath, S; Zerr, P	1
Ahn, HS; Kang, HJ; Kim, H; Kim, MS; Kim, NH; Lee, JW; Park, KD; Shin, HY	1
Amirault, JC; de la Motte Rouge, T; Khaled, W; Vignot, S	1
Adès, L; Bagot, M; Bouaziz, JD; Bourhis, JH; Dalle, JH; de Masson, A; Micol, JB; Nguyen, S; Peffault de Latour, R; Ribaud, P; Robin, M; Rubio, MT; Rybojad, M; Socié, G; Suarez, F; Wittnebel, S; Xhaard, A; Yakouben, K	1
Iwayama, T; Olson, LE	1
Cid, MC; Lozano, E; Segarra, M	1
Wollheim, FA	1
Distler, JH; Distler, O; Gay, RE; Gay, S; Hauser, T; Huber, LC; Jüngel, A; Michel, BA; Schett, G; Schulze-Horsel, U; Zwerina, J	1
Constans, J; Mahon, FX; Taïeb, A	1
Cario-André, M; Lepreux, S; Mahon, FX; Pain, C; Pasquet, JM; Rezvani, HR; Schaeverbeke, T; Soria, A; Taïeb, A	1

Reviews

19 review(s) available for imatinib mesylate and Sclerosis, Systemic

Article	Year
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. Expert review of clinical immunology, 2020, Volume: 16, Issue:9 Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Quality of Life; Scleroderma, Systemic; Skin; Treatment Outcome	2020
Off-Target Effects of BCR-ABL and JAK2 Inhibitors. American journal of clinical oncology, 2016, Volume: 39, Issue:1 Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant	2016
Fulminant capillary leak syndrome in a patient with systemic sclerosis treated with imatinib mesylate. Rheumatology (Oxford, England), 2016, Volume: 55, Issue:10 Topics: Antineoplastic Agents; Biopsy; Capillary Leak Syndrome; Fatal Outcome; Female; Humans; Imatinib Mesylate; Middle Aged; Scleroderma, Systemic	2016
A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis. Journal of the American Academy of Dermatology, 2008, Volume: 59, Issue:4 Topics: Benzamides; Fibrosis; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Raynaud Disease; Scleroderma, Localized; Scleroderma, Systemic; Skin	2008
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford, England), 2008, Volume: 47 Suppl 5 Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Fibrosis; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Scleroderma, Systemic; Skin; Sulfonamides; Thiazoles	2008
Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Current rheumatology reports, 2009, Volume: 11, Issue:2 Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antirheumatic Agents; Benzamides; Cyclophosphamide; Dasatinib; Humans; Imatinib Mesylate; Immunosuppressive Agents; Interleukin-13; Lung Diseases, Interstitial; Mycophenolic Acid; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Respiratory Function Tests; Scleroderma, Systemic; Thiazoles; Treatment Outcome	2009
[Imatinib]. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2009, Volume: 32, Issue:2 Topics: Animals; Benzamides; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Scleroderma, Systemic; Signal Transduction	2009
Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Annals of the rheumatic diseases, 2010, Volume: 69 Suppl 1 Topics: Benzamides; Fibrosis; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic	2010
Future treatments in systemic sclerosis. The Journal of dermatology, 2010, Volume: 37, Issue:1 Topics: Animals; Autoimmune Diseases; B-Lymphocytes; Benzamides; Connective Tissue Growth Factor; Endothelin Receptor Antagonists; Endothelin-1; Humans; Imatinib Mesylate; Immunoglobulins; Mice; Phosphodiesterase 5 Inhibitors; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Transforming Growth Factor beta; Scleroderma, Systemic; Selective Serotonin Reuptake Inhibitors; Smad3 Protein; Transforming Growth Factor beta	2010
Involvement of mast cells in systemic sclerosis. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2010, Volume: 33, Issue:2 Topics: Adaptive Immunity; Animals; Arthritis, Rheumatoid; Benzamides; Disease Models, Animal; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Immunity, Innate; Male; Mast Cells; Mice; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic	2010
The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. Journal of dermatological science, 2010, Volume: 59, Issue:3 Topics: Acetylation; Animals; Autoimmune Diseases; B-Lymphocytes; Benzamides; Collagen Type I; Down-Regulation; Drug Therapy, Combination; Epigenesis, Genetic; Extracellular Matrix; Fibroblasts; Gene Expression; Hematopoiesis; Humans; Imatinib Mesylate; Macrolides; Mice; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Protein c-fli-1; Pyrimidines; Scleroderma, Systemic; T-Lymphocytes	2010
Biologic therapy for systemic sclerosis: a systematic review. The Journal of rheumatology, 2011, Volume: 38, Issue:2 Topics: Antibodies, Monoclonal; Benzamides; Biological Therapy; Etanercept; Humans; Imatinib Mesylate; Immunoglobulin G; Infliximab; Interferon-alpha; Piperazines; Pyrimidines; Receptors, Tumor Necrosis Factor; Scleroderma, Systemic; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha	2011
Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Current rheumatology reports, 2011, Volume: 13, Issue:1 Topics: Animals; Benzamides; Clinical Trials as Topic; Disease Models, Animal; Humans; Imatinib Mesylate; Mice; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Scleroderma, Systemic	2011
Imatinib and the treatment of fibrosis: recent trials and tribulations. Current rheumatology reports, 2011, Volume: 13, Issue:1 Topics: Benzamides; Fibrosis; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic	2011
Immunotherapy of systemic sclerosis. Immunotherapy, 2010, Volume: 2, Issue:6 Topics: Antibodies, Monoclonal; Benzamides; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Immunotherapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Treatment Outcome	2010
Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib. Seminars in arthritis and rheumatism, 2013, Volume: 42, Issue:4 Topics: Benzamides; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic; Treatment Outcome	2013
Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review. Clinical rheumatology, 2012, Volume: 31, Issue:9 Topics: Adolescent; Adult; Autoimmune Diseases; Benzamides; China; Clinical Trials as Topic; Female; Fibrosis; Humans; Imatinib Mesylate; Lung; Middle Aged; Piperazines; Pyrimidines; Scleroderma, Systemic; Time Factors; Treatment Outcome	2012
[Non oncologic applications of molecular targeted therapies]. Bulletin du cancer, 2012, Volume: 99, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Benzamides; Bevacizumab; Drug-Eluting Stents; Humans; Imatinib Mesylate; Immunosuppressive Agents; Macular Degeneration; Molecular Targeted Therapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rituximab; Scleroderma, Systemic; TOR Serine-Threonine Kinases	2012
Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities. Current rheumatology reports, 2013, Volume: 15, Issue:2 Topics: Animals; Benzamides; Fibrosis; Humans; Imatinib Mesylate; Mice; Models, Animal; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic	2013

Trials

3 trial(s) available for imatinib mesylate and Sclerosis, Systemic

Article	Year
Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis research & therapy, 2014, Jul-08, Volume: 16, Issue:4 Topics: Administration, Oral; Adult; Benzamides; Cyclophosphamide; Female; Humans; Imatinib Mesylate; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Middle Aged; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Respiratory Function Tests; Scleroderma, Systemic; Tomography, X-Ray Computed; Treatment Outcome	2014
A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford, England), 2009, Volume: 48, Issue:1 Topics: Adult; Benzamides; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Scleroderma, Systemic; Treatment Outcome	2009
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis and rheumatism, 2011, Volume: 63, Issue:11 Topics: Adult; Benzamides; Female; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic; Treatment Outcome	2011

Other Studies

31 other study(ies) available for imatinib mesylate and Sclerosis, Systemic

Article	Year
Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. Journal of controlled release : official journal of the Controlled Release Society, 2019, 09-28, Volume: 310 Topics: Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Cell Proliferation; Disease Models, Animal; Drug Liberation; Fibroblasts; Gold; Humans; Imatinib Mesylate; Lung; Macrophages, Alveolar; Male; Metal Nanoparticles; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Scleroderma, Systemic	2019
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies. International heart journal, 2020, Volume: 61, Issue:2 Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents	2020
Network-based modeling of drug effects on disease module in systemic sclerosis. Scientific reports, 2020, 08-07, Volume: 10, Issue:1 Topics: Acetylcysteine; Dasatinib; Drug Repositioning; Female; Fibrosis; Genome-Wide Association Study; Humans; Imatinib Mesylate; Indoles; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Scleroderma, Systemic; Signal Transduction	2020
Novel case of a scleroderma-mimicking syndrome associated with gastrointestinal stromal tumour. BMJ case reports, 2021, Mar-04, Volume: 14, Issue:3 Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Raynaud Disease; Scleroderma, Localized; Scleroderma, Systemic; Stomach Neoplasms	2021
Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib). PloS one, 2018, Volume: 13, Issue:5 Topics: Aniline Compounds; Animals; Hydroxyproline; Imatinib Mesylate; Lung; Mice; Mice, Transgenic; Nitriles; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Pulmonary Fibrosis; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Scleroderma, Systemic; Signal Transduction; Skin; src-Family Kinases; Transforming Growth Factor beta1	2018
pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. JCI insight, 2018, 05-03, Volume: 3, Issue:9 Topics: Adult; Animals; Antibiotics, Antineoplastic; Bleomycin; Bronchoalveolar Lavage Fluid; Case-Control Studies; CD4-Positive T-Lymphocytes; Chemokines; Chemotaxis; Dendritic Cells; Disease Models, Animal; Female; Fibrosis; Gene Expression; Humans; Imatinib Mesylate; Inflammation; Interleukin-4; Lung; Male; Mice; Protein Kinase Inhibitors; Receptors, Chemokine; Scleroderma, Systemic; Severity of Illness Index; Skin; Spleen; Transforming Growth Factor beta1; Young Adult	2018
Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts. The Journal of investigative dermatology, 2019, Volume: 139, Issue:2 Topics: Biopsy; Cells, Cultured; Dermis; Fibroblasts; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Organic Cation Transport Proteins; Platelet-Derived Growth Factor; Primary Cell Culture; Protein Kinase Inhibitors; Receptors, Notch; RNA, Small Interfering; Scleroderma, Systemic; Signal Transduction	2019
Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis and rheumatism, 2013, Volume: 65, Issue:11 Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Cell Adhesion; CREST Syndrome; Female; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Male; Piperazines; Pyrimidines; Scleroderma, Systemic; Severity of Illness Index; Skin Physiological Phenomena; Transcriptome	2013
Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Annals of the rheumatic diseases, 2013, Volume: 72, Issue:12 Topics: Adult; Animals; Benzamides; Biopsy; Bleomycin; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fibrosis; Fos-Related Antigen-2; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-sis; Pyrimidines; Scleroderma, Systemic; Skin; Treatment Outcome	2013
Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis and rheumatism, 2008, Volume: 58, Issue:8 Topics: Adult; Aged; Benzamides; Biopsy; Case-Control Studies; Cells, Cultured; Connective Tissue Growth Factor; Female; Fibroblasts; Humans; Imatinib Mesylate; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic; Signal Transduction; Skin; Smad1 Protein; Transforming Growth Factor beta	2008
Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis and rheumatism, 2008, Volume: 58, Issue:8 Topics: Aged; Benzamides; Collagen; Disease Progression; Female; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Scleroderma, Systemic; Treatment Outcome	2008
Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis and rheumatism, 2008, Volume: 58, Issue:8 Topics: Aged; Benzamides; Fibrosis; Humans; Imatinib Mesylate; Kidney Diseases; Knee Joint; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic; Skin; Treatment Outcome	2008
Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone marrow transplantation, 2008, Volume: 42, Issue:11 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Female; Fibroblasts; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Scleroderma, Systemic; Transforming Growth Factor beta; Transplantation, Homologous; Treatment Outcome	2008
Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis and rheumatism, 2009, Volume: 60, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Benzamides; Bleomycin; Disease Models, Animal; Fibrillins; Fibrosis; Imatinib Mesylate; Mice; Mice, Inbred DBA; Mice, Mutant Strains; Microfilament Proteins; Phenotype; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic; Skin; Skin Diseases	2009
Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clinical research in cardiology : official journal of the German Cardiac Society, 2009, Volume: 98, Issue:4 Topics: Animals; Benzamides; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic; Treatment Outcome; Ventricular Dysfunction, Right	2009
Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease? Leukemia & lymphoma, 2009, Volume: 50, Issue:3 Topics: Benzamides; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Scleroderma, Systemic; Treatment Outcome	2009
Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss medical weekly, 2010, Volume: 140 Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Disease Models, Animal; Drugs, Investigational; ErbB Receptors; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Mixed Connective Tissue Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pulmonary Fibrosis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Scleroderma, Systemic; Thiazoles	2010
The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis and rheumatism, 2011, Volume: 63, Issue:6 Topics: Benzamides; Cell Nucleus; Cells, Cultured; Collagen Type I; Dermis; Female; Fibroblasts; Humans; Imatinib Mesylate; Male; Microfilament Proteins; Phosphorylation; Piperazines; Protein Kinase C-delta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Small Interfering; Scleroderma, Systemic; Trans-Activators; Transduction, Genetic; Transforming Growth Factor beta	2011
Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. Modern rheumatology, 2012, Volume: 22, Issue:1 Topics: Aged; Benzamides; Contracture; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Imatinib Mesylate; Male; Middle Aged; Nail Diseases; Nails; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Range of Motion, Articular; Raynaud Disease; Scleroderma, Systemic; Skin; Treatment Outcome	2012
Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis? Arthritis and rheumatism, 2011, Volume: 63, Issue:11 Topics: Benzamides; Early Termination of Clinical Trials; Female; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Diffuse; Scleroderma, Systemic	2011
Is IL-4 a potential therapeutic target in systemic sclerosis-associated pulmonary fibrosis? Clinical immunology (Orlando, Fla.), 2011, Volume: 141, Issue:3 Topics: Benzamides; Bronchoalveolar Lavage Fluid; CD4-Positive T-Lymphocytes; Female; Humans; Imatinib Mesylate; Interleukin-4; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic	2011
Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis. Clinical immunology (Orlando, Fla.), 2011, Volume: 141, Issue:3 Topics: Adult; Antigens, CD; Benzamides; Bronchoalveolar Lavage Fluid; CD4-Positive T-Lymphocytes; Cell Adhesion Molecules; Clinical Trials, Phase II as Topic; Female; Humans; Imatinib Mesylate; Interleukin-4; Lung; Male; Middle Aged; Pilot Projects; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Pyrimidines; Radiography; Scleroderma, Systemic	2011
SSc in 2011: From mechanisms to medicines. Nature reviews. Rheumatology, 2012, Jan-10, Volume: 8, Issue:2 Topics: Benzamides; Blood Coagulation; Clinical Trials as Topic; Fibrosis; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Piperazines; Platelet Activation; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic; Treatment Outcome	2012
Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. The American journal of pathology, 2012, Volume: 181, Issue:5 Topics: Animals; Benzamides; Chronic Disease; Dermis; Disease Models, Animal; Drug Therapy, Combination; Female; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Middle Aged; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic; Signal Transduction	2012
Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD. Pediatric transplantation, 2012, Volume: 16, Issue:8 Topics: Adolescent; Benzamides; Chronic Disease; Creatinine; Drug Administration Schedule; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Male; Piperazines; Pyrimidines; Scleroderma, Systemic; Time Factors; Treatment Outcome	2012
Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood, 2012, Dec-13, Volume: 120, Issue:25 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Benzamides; Child; Child, Preschool; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Localized; Scleroderma, Systemic; Skin; Young Adult	2012
Stimulatory autoantibodies to the PDGF receptor in scleroderma. The New England journal of medicine, 2006, Sep-21, Volume: 355, Issue:12 Topics: Autoantibodies; Autoimmune Diseases; Benzamides; Fibroblasts; Gene Expression Regulation; Genes, ras; Humans; Imatinib Mesylate; Phenotype; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic; Signal Transduction	2006
Treatment of pulmonary fibrosis in systemic sclerosis: light at the end of the tunnel? Arthritis and rheumatism, 2007, Volume: 56, Issue:1 Topics: Animals; Benzamides; Disease Models, Animal; Fibrosis; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrimidines; Scleroderma, Systemic	2007
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis and rheumatism, 2007, Volume: 56, Issue:1 Topics: Aged; Animals; Benzamides; Bleomycin; Cell Proliferation; Cell Survival; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Matrix; Extracellular Matrix Proteins; Female; Fibroblasts; Fibrosis; Gene Expression; Humans; Imatinib Mesylate; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C3H; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrimidines; RNA, Messenger; Scleroderma, Systemic; Skin; Specific Pathogen-Free Organisms	2007
[A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate]. La Revue de medecine interne, 2008, Volume: 29, Issue:3 Topics: Benzamides; Cells, Cultured; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Fibroblasts; Humans; Imatinib Mesylate; Multicenter Studies as Topic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic; Skin	2008
The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology (Basel, Switzerland), 2008, Volume: 216, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blotting, Western; Cell Proliferation; Cells, Cultured; Female; Fibroblasts; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Scleroderma, Systemic; Skin; Treatment Outcome	2008